Full-Time
Clinical Research Associate
Updated on 9/3/2026
Excelya
501-1,000 employees
CRO delivering clinical trial solutions
No salary listed
Île-de-France, France
Hybrid
Hybrid work arrangement in Paris.
 Biology & Biotech (1) |
|---|
Get referred to Excelya
See people who can refer or advise you
- A minimum of 3 years of experience monitoring clinical studies.
- Significant experience with interventional studies, ideally drug studies.
- Good knowledge of private clinical research environments and pharmaceutical company expectations.
- Strong communication, organizational, and independent-working abilities.
- Rigor, teamwork, adaptability, and the ability to collaborate with multiple stakeholders.
- Conduct initiation, monitoring, and close-out visits and write the associated reports.
- Provide operational follow-up for investigator sites and contribute to the smooth conduct of studies.
- Check the quality, consistency, and completeness of clinical data and follow up on queries.
- Ensure compliance with the protocol, Good Clinical Practice, and applicable procedures.
- Monitor the study’s regulatory and essential documentation and ensure its compliance.
- Maintain regular communication with investigators and research teams.
- Support and advise sites on study conduct and resolution of operational issues.
- Identify potential deviations or risks and implement appropriate follow-up actions.
- Experience in oncology and/or hematology.
- Experience with complex studies and/or studies involving high patient volumes.
Excelya provides contract research services to biotech, pharma, and medical device companies, handling the full clinical trial process from operations to data management and regulatory affairs. It offers flexible engagement models—Full-Service, Functional Service Provider (FSP), and Resourcing—so clients can outsource end-to-end trials or specific experts or teams. The company differentiates itself through a people-first culture and growth via acquisitions, building a broad European footprint with capabilities across multiple therapeutic areas. Its goal is to expand its European and global presence while supporting development from early stages through post-market activities, including pharmacovigilance and real-world evidence.
Company Size
501-1,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Boulogne-Billancourt, France
Founded
2014
Get referred to Excelya
See people who can refer or advise you
Simplify's Take
What believers are saying
- Eurazeo's November 24, 2025 financing funds targeted acquisitions and European expansion.
- Excelya says it wants European leadership, serving mid-sized pharma amid sovereignty-driven procurement.
- OCT Europe 2026 highlighted AI, JCA readiness, and real-world evidence capabilities.
What critics are saying
- Excelya posted 0 open roles on August 21, 2026, signaling stalled hiring.
- Eurazeo debt financing increases integration pressure; poorly integrated acquisitions destroy margins by 2027.
- A failed acquisition cycle traps Excelya between debt service and client defections by 2027.
What makes Excelya unique
- Excelya combines Full-Service, FSP, and Resourcing across 28 countries, spanning Europe, the U.S., and India.
- François Moisson and Frédéric Paqueville built a people-first CRO, now backed by Eurazeo since 2025.
- Its integrated clinical, biometrics, regulatory, and medical writing stack reduces sponsor vendor fragmentation.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 5%1 year growth
↑ 8%2 year growth
↑ 8%Excelya earns EcoVadis Bronze Medal in 2026 review. Introduction. Excelya Group is proud to share that Excelya has been awarded the EcoVadis Bronze Medal following its 2025/2026 reassessment. This recognition places Excelya Group in the top 35% of companies evaluated and reflects its continued dedication to responsible, ethical, and sustainable business practices. This achievement is especially meaningful given two major changes in this year's evaluation process: the full integration of Scope 3 carbon footprint calculations, along with the shift to non-rounded scoring, provides a more precise and rigorous assessment framework. Its 2026 EcoVadis results. Despite the more rigorous criteria, Excelya Group achieved a score nearly identical to last year, demonstrating the strength and consistency of its CSR foundations * Environment: 78/100 * Ethics: 70/100 * Sustainable Procurement: 69/100 * Overall Score: 71/100 (84th percentile) * Labor & Human Rights: 68/100 What this means for its future? While Excelya Group is encouraged by these results, Excelya Group recognize that sustainability is a continuous journey. Looking ahead to 2026, Excelya Group is committed to advancing its CSR strategy even further through two key initiatives: * Comprehensive Carbon Footprint Assessment: Excelya Group is partnering with Ecodev to implement a structured and comprehensive carbon footprint assessment that will give Excelya Group deeper insights into its environmental impact across all scopes. * Science Based Targets Initiative (SBTi) Alignment: Excelya Group is working toward aligning its climate goals with the Science Based Targets initiative, ensuring its emissions reduction targets are grounded in climate science and contribute meaningfully to limiting global warming. Moving forward together. This Bronze Medal isn't just recognition of where Excelya Group is, it's the foundation for where Excelya Group is going. Sustainability isn't a side initiative; it's embedded in how Excelya Group operate, support its clients, and empower its people. As Excelya Group continue to strengthen its CSR commitments, Excelya Group stay focused on delivering excellence while caring for its planet, its teams, and its communities. Thank you to every Excelyate who helps make sustainability a true value at Excelya. To learn more about Excelya's CSR and sustainability efforts, learn more about Excelya's CSR and sustainability efforts.
Morgan Lewis has advised Eurazeo on its investment in Excelya, a European clinical research services provider. The deal sees Eurazeo join as a long-term investor alongside Excelya's management team. Eurazeo, a leading European investment group, manages €37.4 billion in diversified assets and supports over 600 mid-market companies. Excelya specialises in developing patient treatments and advancing scientific knowledge in clinical research. The Morgan Lewis team included partners Sophie Perus and Sebastien Pontillo, of counsel Thomas Lefebvre, and associates Baptiste Godmer, Charles Deffontaines and Camille Jannin. Financial terms of the investment were not disclosed.
Eurazeo is joining Excelya, a European clinical research services provider, as a lead investor alongside its management team to support the Group in continuing its development and pursuing external...